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Rationale: Forced vital capacity (FVC) is an established measure of
pulmonary function in idiopathic pulmonary fibrosis (IPF). Evidence
regarding its measurement properties andminimal clinically impor-
tant difference (MCID) in this population is limited.
Objectives: To assess the reliability, validity, and responsiveness of
FVC and estimate the MCID in patients with IPF.
Methods: The study population included all 1,156 randomized
patients in two clinical trials of IFN-g1b. FVC and other measures of
functional status were measured at screening or baseline and
24-week intervals thereafter. Reliability was assessed based on two
proximal measures of FVC, validity was assessed based on correla-
tions between FVC and other measures of functional status, and
responsiveness was assessed based on the relationship between
24-week changes in FVC and other measures of functional status.
Distribution-based and anchor-based methods were used to esti-
mate the MCID.
Measurements and Main Results: Correlation of percent-predicted
FVCbetweenmeasurements (mean interval, 18d)washigh(r¼0.93;
P , 0.001). Correlations between FVC and other parameters were
generally weak, with the strongest observed correlation between
FVC and carbon monoxide diffusing capacity (r ¼ 0.38; P , 0.001).
Correlations between change in FVC and changes in other parame-
ters were slightly stronger (range, r¼ 0.16–0.37; P, 0.001). Impor-
tantly, 1-year risk of deathwasmore than twofoldhigher (P,0.001)
in patientswith a 24-week decline in FVC between 5%and 10%. The
estimated MCID was 2–6%.
Conclusions: FVC is a reliable, valid, and responsive measure of clin-
ical status inpatientswith IPF, andadeclineof2–6%,althoughsmall,
represents a clinically important difference.
Keywords: interstitial lung disease; idiopathic pulmonary fibrosis;
forced vital capacity; minimal clinically important difference; mortality
prediction
Idiopathic pulmonary fibrosis (IPF) is a progressive, life-threatening,
interstitial lung disease of unknown etiology. It is characterized an-
atomically by scarring of the lungs and symptomatically by exer-
tional dyspnea. IPF is the most common diffuse fibrosing lung
disease and one of the most lethal, with a median survival of only
2 to 3 years after diagnosis (1–3).
Forced vital capacity (FVC) has been a standard spirometric
measure of pulmonary function in IPF for many decades. Lon-
gitudinal change in serial measures of lung volume (either FVC
or vital capacity) is a widely accepted reflection of disease pro-
gression in patients with IPF and a commonly used primary end-
point in therapeutic studies in IPF (4–8). Moreover, several
studies have identified change in percent-predicted FVC as an
independent predictor of mortality in patients with IPF (9–14).
Despite its widespread usage and clear prognostic utility, the
measurement properties of percent-predicted FVC in IPF have
not been formally examined. Furthermore, the minimal clini-
cally important difference (MCID) in percent-predicted FVC
among patients with IPF is currently unknown.
TheMCID is the smallest difference in a measure that may be
perceived to be important, either beneficial or harmful, and that
would lead a clinician to consider a change in a patient’s therapy
(15, 16). MCID is a clinically important concept, because it may
assist with the interpretation of the significance of observed
changes in a measure and may influence the perceived efficacy
of an intervention. The MCID also may have implications for
the design of clinical trials in terms of the selection of primary
and secondary endpoints and the determination of sample size
(17, 18).
In the present study, we used data from two of the largest clin-
ical trials to date in patients with IPF to assess the reliability, val-
idity, and responsiveness of FVC and estimate the MCID in
patients with this disease. This study has been presented in part
at the 2010 European Respiratory Society Annual Congress (19).
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AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Forced vital capacity (FVC) is a widely used measure of
disease status and a common endpoint in clinical trials in
patients with idiopathic pulmonary fibrosis. However, the
measurement properties of FVC in this population have not
been systematically evaluated.
What This Study Adds to the Field
Our findings demonstrate that FVC is a reliable, valid, and
responsive measure of disease status in patients with idio-
pathic pulmonary fibrosis and suggest that the minimal
clinically important difference for percent-predicted FVC is
between 2% and 6%.
METHODS
Study Population
The study population comprised all randomized subjects (n ¼ 1,156)
in two placebo-controlled clinical trials of IFN-g1b (Protocols GIPF-
001 [n ¼ 330] and GIPF-007 [n ¼ 826]) irrespective of treatment assign-
ment (placebo [n ¼ 443] or IFN-g1b [n ¼ 713]), given that both of these
studies were negative. The designs of these trials are described in detail
elsewhere (20, 21). Briefly, eligible patients were required to have a high-
resolution computed tomography scan showing features consistent with
protocol-defined criteria for either a definite or probable diagnosis of
IPF. Surgical lung biopsy was required to confirm a suspected diagnosis
in all patients with a clinical and radiographic diagnosis of probable IPF,
and all patients less than age 50 years, regardless of the degree of cer-
tainty associated with the clinical and radiographic diagnoses.
Data Collection
Data collected in the aforementioned trials included patient demographic
and clinical characteristics (age, sex, duration of disease [from date of IPF
diagnosis], smoking status, and use of supplemental oxygen); physiologic
assessments (percent-predicted FVC, percent-predicted carbonmonoxide
diffusing capacity [DLCO], and resting alveolar–arterial oxygen pressure
at ambient temperature [A-a gradient]); measures of functional status
(6-minute-walk distance [6MWD], in Protocol GIPF-007), dyspnea (Uni-
versity of California at San Diego Shortness of Breath Questionnaire
[UCSD-SOBQ]), and health-related quality of life (HRQL; St. George’s
Respiratory Questionnaire [SGRQ] and Medical Outcomes Study
36-item short-form [SF-36], the latter in Protocol GIPF-001); hospital-
izations; and vital status. Total score on the UCSD-SOBQ ranges from
0–120, with higher scores reflecting worse dyspnea (22). The SGRQ
comprises three respiratory-specific domains (symptoms, activity, and
impacts) and each domain ranges from 0–100, with an increasing score
indicating worsening HRQL (23).
Information on percent-predicted FVC, percent-predicted DLco,
A-a gradient (Protocol GIPF-001), 6MWD (Protocol GIPF-007), dysp-
nea, and HRQL was collected at the screening or baseline visit and
periodically (i.e., every 12 wks in Protocol GIPF-001 and every 24 wks
in Protocol GIPF-007) thereafter through the end of the trial. Resting
A-a gradient was assessed at the screening visit and every 48 weeks
thereafter in Protocol GIPF-007. Hospitalizations and vital status were
tracked throughout the conduct of the trials.
Statistical Analyses
Reliability. Reliability was assessed based on the stability of percent-
predicted FVC values between the study screening visit (Day 228 to
Day 21) and the baseline visit (Day 1). The intraclass correlation
coefficient was used to assess the strength of the relationship between
these assessments; a value of 0.80 or greater was assumed to represent
“good” reliability. Analyses were conducted using observed data for all
subjects with FVC values from both the screening and baseline visits in
Protocol GIPF-001 (screening data on percent-predicted FVC were not
collected in Protocol GIPF-007).
Validity. Criterion validity was assessed based on relationships be-
tween percent-predicted FVC and the following parameters at the same
visit: percent-predicted DLCO, A-a gradient, 6MWD, UCSD-SOBQ,
SGRQ, and SF-36. Distribution-independent (Spearman) correlation
coefficients were used to assess the strength of these relationships.
Strength of correlation was designated as follows: greater than
0.5, large; 0.5–0.3, moderate; 0.3–0.1, small; and less than 0.1, trivial
(24).
Construct validity was assessed by comparing mean percent-
predicted FVC values across subgroups of patients presumed to have
different levels of physiologic function, defined on the basis of
percent-predicted DLCO, A-a gradient, 6MWD, UCSD-SOBQ, SGRQ,
and SF-36 at the same visit. Patients were stratified into subgroups
based on the quintiles of the corresponding distributions. One-way
analysis of variance was used for statistical comparisons.
Responsiveness. Responsiveness was assessed using Spearman corre-
lation coefficients between changes (i.e., screening and baseline toWeek
24) in percent-predicted FVC and changes over the same period in
percent-predicted DLCO, A-a gradient, 6MWD, UCSD-SOBQ, SGRQ,
and SF-36. The relationship between mean changes in percent-
predicted FVC and changes in other measures (stratified into quintiles)
was examined using analysis of variance. Analyses were conducted
using observed data for the full study population.
Responsiveness was also evaluated by examining the relationship be-
tween change in percent-predicted FVC over 24 weeks and 1-year risk of
death using a Cox proportional hazards model. Change in percent-
predicted FVC was evaluated over the 24-week periods immediately
preceding the Week 24 and Week 72 trial visits, respectively, and
was defined categorically (i.e., absolute change in percent-predicted
FVC < 210%, 25% to 29%, . 25%) based on prior research (9–
14). All deaths occurring over the 48-week period after the Week 24
and Week 72 trial visits, respectively, were included in these analyses;
subjects who were lost to follow-up and those who underwent lung
transplant during follow-up were censored on the corresponding date.
Potential confounding from the inclusion of subjects receiving active
drug during follow-up was evaluated by including a term in the model
for treatment assignment and an interaction term for treatment assign-
ment and change in percent-predicted FVC; percent-predicted FVC at
baseline (i.e., baseline trial visit and Week 48 trial visit, respectively)
was also included as a model covariate. The assumption of proportional
hazards was evaluated using published methods (25).
Minimal clinically important difference. Both distribution-based and
anchor-based methods were used to estimate the MCID. Distribution-
based methods included the SEM and effect size. SEM was calculated
for percent-predicted FVC by multiplying the estimated standard devia-
tion at baseline for all randomized subjects by the square root of one mi-
nus the estimated reliability coefficient (26, 27). One SEM was defined to
be the MCID. Because the SEM is sample-independent, corresponding
estimates are considered to be bidirectional in nature. Analyses were
repeated using estimates of standard deviation for percent-predicted
FVC at Weeks 24, 48, 72, and 96, respectively.
Effect size was calculated by dividing the difference inmean percent-
predicted FVC at baseline andWeek 48 by the standard deviation of this
measure at baseline. A change in value corresponding to a “small” effect
size, defined as 0.2 to less than 0.5, per conventional benchmarks, was
considered to approximate the MCID (17, 24, 28, 29). One-third of the
estimated standard deviation has also been suggested as an approxi-
mation of MCID (30). Analyses were repeated evaluating the differ-
ence in mean percent-predicted FVC over alternative 48-week
intervals (i.e., Weeks 24–72 and Weeks 48–96) and intervals of differ-
ent durations (i.e., Weeks 0–24, Weeks 0–72, and Weeks 0–96).
Anchor-based methods included the patient-referencing and
criterion-referencing approaches. The patient-referencing approach
compared the mean change in percent-predicted FVC between baseline
and Week 48 across subgroups of patients defined on the basis of their
global rating of change in health status at Week 48. Determination of
change in global health status was based on the following question from
the SF-36: “Compared with one year ago, how would you rate your
health in general now”? Possible responses to this question were as
follows: (1) “much better,” (2) “somewhat better,” (3) “same,” (4)
“somewhat worse,” and (5) “much worse.” The second and fourth
responses (i.e., somewhat better and somewhat worse, respectively)
were considered to represent minimal but clinically important changes;
in these analyses, the valence of change in percent-predicted FVC was
reversed for patients reporting worse health (31). Mean changes in
percent-predicted FVC were examined on both an unadjusted and an
adjusted basis. FVC mean change values were adjusted for the mean
change in the group reporting no change in global health status to
account for potential recall bias in patient responses, and thus to “nor-
malize” change scores relative to the group of patients who rated their
health status as “the same” as 1 year ago. Data for all randomized
subjects in Protocol GIPF-001 were used in these analyses; analyses
were repeated evaluating change in percent-predicted FVC between
Weeks 12 and 60, and Weeks 24 and 72, respectively.
The criterion-referencing approach involved estimation of differen-
ces in percent-predicted FVC at baseline between patients who did and
did not experience selected health events (specifically, all-cause hospi-
talization, death, and the composite endpoint, hospitalization or death)
during the subsequent 48-week period. An independent samples t test
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was used for statistical comparisons. Analyses were conducted using
observed data from all randomized subjects who were not lost to
follow-up during the 48-week period.
RESULTS
Patient Characteristics
A total of 1,156 patients were randomized either to placebo (n¼
443) or IFN-g1b (n ¼ 713) in the two clinical trials (Protocols
GIPF-001 [n ¼ 330] and GIPF-007 [n ¼ 826]) (Table 1). Mean
(6 SD) age at study entry was 65 (6 8) years and 70% of
patients were male. The mean value for percent-predicted
FVC at baseline was 70.1% (12.8) and the interquartile range
was 60–78.7%. There was substantial variation across study sub-
jects in measures of physiologic function, functional status,
dyspnea, and HRQL.
Reliability
Percent-predicted FVC seems to have good reliability in patients
with IPF. The intraclass correlation coefficient between percent-
predicted FVC values (n ¼ 91) at the screening and baseline
visits (mean number of days between visits, 18) was 0.93 (P ,
0.001). There were no apparent differences in correlation coef-
ficients for percent-predicted FVC values based on age or sex
(data not shown).
Validity
The relationship between percent-predicted FVC and other
measures of disease status is summarized in Tables 2 and 3.
Correlations between percent-predicted FVC and measures of
gas exchange, functional status, dyspnea, and HRQL were in
the expected direction but generally weak (absolute values of
all coefficients, ,0.17, except for percent-predicted DLCO [r ¼
0.38; P , 0.001]) (Table 2). Mean values for percent-predicted
FVC were generally significantly lower for patients with poorer
levels of gas exchange, functional status, dyspnea, and HRQL;
percent-predicted FVC did not vary across quintiles of patients
defined on the basis of the SF-36 (Table 3).
Responsiveness
Correlations between changes in percent-predicted FVC and
changes inmeasures of physiologic function, functional status, dysp-
nea, and HRQL were in the expected direction, but moderately
to weakly correlated (absolute values of all coefficients, ,0.37)
(Table 4). Decline in percent-predicted FVC was consistently
greater for patients with larger declines in levels of physiologic
function, functional status, and HRQL (Table 5). Findings were
largely unchanged when focusing on each of the respective treat-
ment groups from the clinical trials and when assessing changes
over a different period of time (i.e., 48 wk).
Change in percent-predicted FVC over 24 weeks was highly
predictive of death over the subsequent 1-year period. Risk of
death was nearly fivefold higher (hazard ratio, 4.78; 95% con-
fidence interval [CI], 3.12–7.33; P , 0.001) for patients with ab-
solute declines in percent-predicted FVC of greater than or equal
to 10% (e.g., a decline from 70–60%), and more than twofold
higher (hazard ratio, 2.14; 95% CI, 1.43–3.20; P, 0.001) for those
with absolute declines between 5% and 10%, compared with
patients who experienced declines in percent-predicted FVC of
less than 5% (Table 6). Treatment assignment and the interaction
term for treatment assignment and change in percent-predicted
FVC (defined continuously) were not found to be important pre-
dictors of death, and the proportional hazards assumption for
change in percent-predicted FVC was not violated.
Minimal Clinically Important Difference
The estimated SEM for percent-predicted FVC, and the corre-
sponding MCID, was 3.4 (95% CI, 3.2–3.5) (Table 7). Using
observed data from postbaseline visits, the estimated SEM
ranged from 3.8–4.3. The estimated effect size for percent-
predicted FVC was 0.27 (95% CI, 0.23–0.31), based on a differ-
ence in mean baseline and mean Week 48 values of 3.4%;
TABLE 1. BASELINE CHARACTERISTICS
Characteristic Value*
Age, yr
Mean (SD) 65.3 (8.1)
Median (IQR) 66 (60–72)
Sex, n (%)
Male 812 (70.2)
Female 344 (29.8)
FVC, % predicted
Mean (SD) 70.1 (12.8)
Median (IQR) 68 (60–78.7)
DLCO, % predicted
Mean (SD) 44.4 (10.8)
Median (IQR) 43.9 (37–50.8)
Resting AaPo2, mm Hg
Mean (SD) 20.8 (11.1)
Median (IQR) 20.4 (13–28.2)
6MWT distance, m
Mean (SD) 392.4 (108.5)
Median (IQR) 395 (328–462)
UCSD SOBQ score
Mean (SD) 37.9 (23.5)
Median (IQR) 35 (19.6–55)
SGRQ score
Mean (SD) 43.8 (17.7)
Median (IQR) 43.6 (31–56.2)
SF-36 MCS
Mean (SD) 50.6 (10.2)
Median (IQR) 52.1 (43–59.3)
SF-36 PCS
Mean (SD) 34.5 (8.6)
Median (IQR) 33.2 (28.2–40.4)
Definition of abbreviations: 6MWT ¼ 6-minute-walk test; AaPo2 ¼ alveolar–
arterial oxygen gradient; DLCO ¼ carbon monoxide diffusion capacity; IQR ¼
interquartile range; SF-36 MCS ¼ Medical Outcomes Study 36-item short form
(mental component summary); SF-36 PCS ¼ Medical Outcomes Study 36-item
short form (physical component summary); SGRQ ¼ St. George’s Respiratory
Questionnaire; UCSD SOBQ ¼ University of California San Diego Shortness of
Breath Questionnaire.
* n ¼ 1,156 except for DLCO (1,152); AaPo2 (1,139); 6MWT distance (822);
UCSD SOBQ (1,120); SGRQ (1,060); SF-36 MCS (307); and SF-36 PCS (307).
TABLE 2. CORRELATION BETWEEN PERCENT-PREDICTED FVC
AND OTHER MEASURES
Variable N Coefficient* P Value†
DLCO, % predicted 1,152 0.38 ,0.001
Resting AaPo2,, mm Hg 1,139 20.17 ,0.001
6MWT distance, m 822 0.12 ,0.001
UCSD SOBQ score 1,120 20.17 ,0.001
SGRQ score 1,060 20.16 ,0.001
SF-36 MCS 307 0.00 0.944
SF-36 PCS 307 0.14 0.015
Definition of abbreviations: 6MWT ¼ 6-minute-walk test; AaPo2 ¼ alveolar–
arterial oxygen gradient; DLCO ¼ carbon monoxide diffusion capacity; SF-36
MCS ¼ Medical Outcomes Study 36-item short form (mental component sum-
mary); SF-36 PCS ¼ Medical Outcomes Study 36-item short form (physical com-
ponent summary); SGRQ ¼ St. George’s Respiratory Questionnaire; UCSD SOBQ ¼
University of California San Diego Shortness of Breath Questionnaire.
* Spearman correlation coefficient.
y One-way analysis of variance.
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according to Cohen’s criteria (24), such an effect should be
considered “small.” Similar results were obtained when focusing
on alternative time intervals, with effect sizes ranging from
0.15–0.46 based on differences in mean values for percent-
predicted FVC ranging from 2–6%. One-third of the estimated
standard deviation at baseline yielded a figure of 4.2; figures
based on data from other visits ranged from 4.2–4.9.
Patients who reported that their global health status was
“much better” at Week 48 versus baseline experienced an (un-
adjusted) absolute increase in percent-predicted FVC of 2.3%,
on average; patients reporting that their global health status was
“somewhat better,” “same,” “somewhat worse,” or “much
worse” experienced decreases in percent-predicted FVC
(22.1%, 22.8%, 26.5%, and 26.1%, respectively). On an ad-
justed basis, mean change in percent-predicted FVC for the
subgroup who reported that their health status was “somewhat
better” or “somewhat worse,” which was considered to
represent the MCID, was 2.2%. In analyses using change in
percent-predicted FVC between Weeks 12 and 60 and change
between Weeks 24 and 72, respectively, corresponding esti-
mates of MCID were 2.7% and 4.3%.
Criterion-referencing analyses demonstrated that values for
percent-predicted FVC at baseline were significantly different
for patients who died versus those who did not during the
48-week follow-up period. Mean (6 SD) baseline percent-
predicted FVC in patients who died during the 48-week
follow-up period was 64.9% (6 11.2), compared with 70.7%
(6 12.8) in those who survived. Based on this difference, the
estimated MCID was 5.8% (P , 0.001).
DISCUSSION
FVC is a widely used measure of pulmonary function and disease
status in patients with IPF. Despite its ubiquitous use in clinical
practice and therapeutic clinical trials, FVC test performance
characteristics in patients with IPF have not been formally eval-
uated. Additionally, theMCID for percent-predicted FVC in this
patient population is currently unknown. The present study
assessed reliability, validity, and responsiveness of FVC and es-
timated the MCID in a large cohort of patients with a confident
IPF diagnosis and mild to moderate impairment in measures of
baseline physiologic function. Taken collectively, the data sug-
gest that percent-predicted FVC is a robust measure of clinical
status in patients with IPF.
Reliability, as assessed by the stability of two proximal measures
of FVC, was found to be good, with an overall interclass correlation
coefficient of 0.93. Comparison of baseline percent-predicted
FVC values with selected measures of physiologic function,
dyspnea, and HRQL revealed generally weak correlations; how-
ever, comparison of mean values for percent-predicted FVC
across quintiles defined on the basis of other measures demon-
strated consistently lower values for patients with poorer levels
of performance on these measures. Responsiveness, as measured
by the correlation between change in FVC and changes in other
parameters, was slightly stronger, with coefficients consistently
in the range of 0.16–0.37. Additionally, change in percent-
predicted FVC was found to be highly predictive of mortality.
Although the objective of this analysis (i.e., to evaluate respon-
siveness) was different from that of prior research (i.e., to eval-
uate independent effect), our findings are consistent with
observations from previous studies (9–14). Specifically, a decline
in percent-predicted FVC greater than or equal to 10% at
24 weeks was associated with a nearly fivefold increase in the
risk of mortality over the subsequent year, whereas a decline of
TABLE 4. CORRELATION BETWEEN CHANGE IN
PERCENT-PREDICTED FVC AND CHANGE IN OTHER MEASURES
Variable N Coefficient* P Value†
DLCO, % predicted 1,047 0.29 ,0.001
Resting AaPo2, mm Hg 290 20.37 ,0.001
6MWT distance, m 762 0.22 ,0.001
UCSD SOBQ score 1,001 20.25 ,0.001
SGRQ score 897 20.32 ,0.001
SF-36 MCS 246 0.16 0.012
SF-36 PCS 246 0.26 ,0.001
Definition of abbreviations: 6MWT ¼ 6-minute-walk test; AaPo2 ¼ alveolar–
arterial oxygen gradient; DLCO ¼ carbon monoxide diffusion capacity; SF-36
MCS ¼ Medical Outcomes Study 36-item short form (mental component sum-
mary); SF-36 PCS ¼ Medical Outcomes Study 36-item short form (physical com-
ponent summary); SGRQ ¼ St. George’s Respiratory Questionnaire; UCSD SOBQ ¼
University of California San Diego Shortness of Breath Questionnaire.
* Spearman correlation coefficient.
y One-way analysis of variance.
TABLE 3. MEAN (SD) PERCENT-PREDICTED FVC BY QUINTILES
OF OTHER MEASURES
Variable N % Predicted FVC* P Value†
DLCO, % predicted
,36.00 221 63.1 (10.5) ,0.001
>36.00 to ,41.02 239 67.4 (10.9) ,0.001
>41.02 to ,46.44 231 69.2 (11.3) ,0.001
>46.44 to ,52.73 230 73.1 (12.6) ,0.001
>52.73 231 77.3 (13.8) —
Resting AaPo2, mm Hg
,10.89 228 72.4 (12.2) ,0.001
>10.89 to ,17.50 227 71.1 (12.3) ,0.001
>17.50 to ,23.50 228 71.3 (12.6) ,0.001
>23.50 to ,29.58 229 69.3 (13.5) 0.009
>29.58 227 66.2 (13.4) —
6MWT distance, m
,306 163 70.4 (12.6) ,0.001
>306 to ,369 165 71.4 (11.9) 0.010
>369 to ,419 162 72.5 (11.8) 0.064
>419 to ,480 165 73.1 (13.1) 0.169
>480 167 75 (13.6) —
UCSD SOBQ score
,15.83 224 74 (13.5) ,0.001
>15.83 to ,27.37 224 70.4 (12.6) 0.002
>27.37 to ,42.00 214 70.4 (11.6) 0.003
>42.00 to ,59.00 223 68.6 (12.3) 0.124
>59.00 235 66.8 (12.5) —
SGRQ score
,28.09 212 73.1 (12.8) ,0.001
>28.09 to ,38.11 212 70.4 (13.2) 0.003
>38.11 to ,48.18 212 69.7 (12) 0.015
>48.18 to ,59.60 211 68.6 (12.8) 0.139
>59.60 213 66.8 (11.5) —
SF-36 MCS
,40.98 61 63.7 (11.2) 0.870
>40.98 to ,48.66 61 63.9 (11.8) 0.935
>48.66 to ,55.82 62 63.6 (10.9) 0.808
>55.82 to ,60.42 62 63.8 (10.4) 0.890
>60.42 61 64 (10.9) —
SF-36 PCS
,26.83 61 63.2 (9.9) 0.410
>26.83 to ,31.22 62 61.3 (10.3) 0.075
>31.22 to ,36.22 61 62.6 (11.8) 0.251
>36.22 to ,42.23 62 67 (11.4) 0.267
>42.23 61 64.8 (10.8) —
Definition of abbreviations: 6MWT ¼ 6-minute-walk test; AaPo2 ¼ alveolar–
arterial oxygen gradient; DLCO ¼ carbon monoxide diffusion capacity; SF-36
MCS ¼ Medical Outcomes Study 36-item short form (mental component sum-
mary); SF-36 PCS ¼ Medical Outcomes Study 36-item short form (physical com-
ponent summary); SGRQ ¼ St. George’s Respiratory Questionnaire; UCSD SOBQ ¼
University of California San Diego Shortness of Breath Questionnaire.
* Data are presented as mean (SD).
y One-way analysis of variance.
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5–10% conferred a more than twofold increase in the risk of
1-year mortality. This latter finding is particularly noteworthy,
because it supports recent data suggesting that changes in
percent-predicted FVC that were previously regarded as evi-
dence of clinically stable disease are medically relevant and
worthy of further clinical evaluation (13).
Consistent with the recommendations of Yost and Eton (30),
we used a number of alternative methods to estimate the MCID
for percent-predicted FVC, including distribution-based and
anchor-based approaches, and we report a range of estimates
of the MCID. Our results suggest that the MCID for percent-
predicted FVC lies between 2% and 6% based on these various
alternative methods of estimation. We note, however, that the
upper limit of this range may not appropriately reflect the small-
est difference that would be clinically important to patients with
IPF because it was estimated using an anchor-based method
that used death as a health event, which is clearly not minimally
important in nature. We also note that the lower limit of this
range may not reflect the MCID because a value lower than 3%
was observed in only one of the many different analyses used,
and this estimate was generated using data on a relatively small
sample of patients (n ¼ 114) from only one of the two clinical
trials. In addition, measurement error may limit the use of small
MCID values in the assessment of an individual patient; for this
reason, it has been suggested that the high end of the range
should be used to assess the clinical relevance of changes in
an individual patient, whereas the lower limit of the range
should be used to assess change at the population level (30).
Importantly, our estimates of MCID were largely unchanged
(maximum value, 5%) when using data from other visits and
over intervals of different durations. This finding, coupled with
the similarity of the estimates derived by the various alternative
analytic approaches, demonstrates a high degree of internal
consistency. Moreover, our findings are remarkably consistent
with those of a recent study by Zappala and coworkers (13),
which evaluated the prognostic significance of marginal declines
in percent-predicted FVC in 84 patients with biopsy-proved
IPF. A post hoc analysis of mortality risk at various thresholds
of change in percent-predicted FVC at 6 months suggested that
the optimal threshold value was between 23% and 24%.
Several study limitations should be noted. First, reliability of
percent-predicted FVC was assessed using data from a relatively
small subgroup of patients (n ¼ 91) for whom both screening and
baseline values were available. The analysis was limited to these
data because the mean interval between the screening and base-
line visits was only 18 days, compared with the relatively long
intervals between postbaseline visits in GIPF-001 and GIPF-007
(12 and 24 wk, respectively). This allowed us to minimize poten-
tial confounding from changes in disease status and other factors.
Of note, this subgroup was not clinically or statistically different
in terms of their baseline characteristics from other patients en-
rolled in GIPF-001. Second, although the analyses of responsive-
ness ideally would have been limited to patients randomized to
the placebo arm in the clinical trials, we concluded based on the
absence of evidence for any treatment effect that the enhanced
power of the study to characterize the relationship between
changes in percent-predicted FVC and changes in other measures
of disease status justified the inclusion of all randomized patients.
Analyses of responsiveness and all other analyses (reliability,
validity, and MCID) were robust when focusing on different
populations (e.g., all subjects vs. placebo subjects) and when
assessing changes over different periods of time (e.g., 24 vs.
48 wk). Third, although the SEM is sample-independent and
the corresponding estimates of MCID should therefore be con-
sidered bidirectional in nature, findings from the patient-
referencing approach suggest that perceived gains and losses
TABLE 5. MEAN (SD) CHANGE IN PERCENT-PREDICTED FVC BY
QUINTILES OF CHANGE IN OTHER MEASURES
Variable N % Predicted FVC* P Value†
DLCO, % predicted
,28.00 208 26 (7.2) ,0.001
>28.00 to ,24.17 212 22.6 (6.3) ,0.001
>24.17 to ,21.00 203 21.5 (6.4) ,0.001
>21.00 to ,2.84 215 20.8 (5.6) ,0.001
>2.84 209 1.4 (6.6) —
Resting AaPo2, mm Hg
,26.52 59 1 (5.4) ,0.001
>26.52 to ,21.44 57 20.4 (7) ,0.001
>21.44 to ,3.20 57 20.8 (4.4) ,0.001
>3.20 to ,7.46 58 23.8 (6) 0.242
>7.46 59 25 (5.6) —
6MWT distance, m
,272.00 151 24.7 (7.5) ,0.001
>272.00 to ,223.00 152 22.3 (6.5) 0.011
>223.00 to ,1.00 148 21.6 (6.8) 0.091
>1.00 to ,32.00 157 20.9 (7.6) 0.395
>32.00 154 20.2 (6.8) —
UCSD SOBQ score
,29.00 189 0.1 (6.6) ,0.001
>29.00 to ,21.00 208 21.3 (6.6) ,0.001
>21.00 to ,5.00 203 21.4 (5.6) ,0.001
>5.00 to ,14.82 203 22.1 (6) ,0.001
>14.82 198 24.9 (7.5) —
SGRQ score
,28.61 181 0.9 (7.4) ,0.001
>28.61 to ,22.59 179 21.1 (6.3) ,0.001
>22.59 to ,2.65 178 21.3 (6.5) ,0.001
>2.65 to ,10.02 180 22.9 (6) ,0.001
>10.02 179 25.3 (7.4) —
SF-36 MCS
,27.26 48 22.3 (8.1) 0.334
>27.26 to ,21.96 50 22.1 (6.1) 0.409
>21.96 to ,2.05 50 21.9 (6.1) 0.485
>2.05 to ,6.98 50 20.9 (4.8) 0.911
>6.98 48 21 (5.6) —
SF-36 PCS
,25.90 48 23.7 (5.8) ,0.001
>25.90 to ,21.87 50 23.2 (5.6) ,0.001
>21.87 to ,1.28 49 20.9 (6.6) 0.059
>1.28 to ,6.21 50 21.7 (5.6) 0.010
>6.21 49 1.4 (6.2) —
Definition of abbreviations: 6MWT ¼ 6-minute-walk test; AaPo2 ¼ alveolar–
arterial oxygen gradient; DLCO ¼ carbon monoxide diffusion capacity; SF-36
MCS ¼ Medical Outcomes Study 36-item short form (mental component sum-
mary); SF-36 PCS ¼ Medical Outcomes Study 36-item short form (physical
component summary); SGRQ ¼ St. George’s Respiratory Questionnaire; UCSD
SOBQ ¼ University of California San Diego Shortness of Breath Questionnaire.
* Data are presented as mean (SD).
y One-way analysis of variance.
TABLE 6. COX PROPORTIONAL HAZARDS MODEL
Patient Visits (n) Deaths (n)
1-Year Risk of Death
HR (95% CI) P Value
DFVC, % predicted
<210 166 39 4.78 (3.12–7.33) ,0.001
25 to 210 373 45 2.14 (1.43–3.20) ,0.001
.25 1,316 56
FVC, % predicted
<50 203 42 7.44 (3.28–16.87) ,0.001
51 to 65 691 65 4.09 (1.87–8.98) ,0.001
66 to 79 594 26 1.97 (0.85–4.55) 0.111
>80 374 7
Definition of abbreviations: DFVC ¼ 24-week absolute change in percent-
predicted FVC (e.g., change from 70–65%¼ 5% absolute change); CI¼ confidence
interval; HR ¼ hazard ratio.
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may not be equivalent vis-a`-vis change in FVC; small sample
sizes in the latter analyses precluded a more thorough investiga-
tion of this issue. Fourth, in our criterion-referencing approach to
estimating the MCID, we used hospitalization and death from
any cause as health events. Clearly, these events are not mini-
mally important in nature; as a result, estimates based on this
approach may not appropriately reflect the smallest differences
that would be clinically important to patients with IPF. These
estimates may thus be viewed as conservative, although they were
largely consistent with estimates yielded by the other approaches.
Fifth, the clinical trials from which data were used for this study
enrolled a group of patients with mild-to-moderate impairment of
pulmonary function at baseline; patients who were too ill or con-
sidered at high risk for dying during the course of the trial were
excluded from the trial populations. It is thus unknown whether
the measurement properties and MCID for percent-predicted
FVC would be comparable in a population of patients with more
severe IPF. Finally, for each of the various analyses, we used all
observed data rather than limiting the study population to
patients with complete information on all measures at all times
or using an imputation algorithm to estimate missing values; thus,
the size of the population and mix of patients may have varied
across analyses. In addition, although the exclusion of patients
in some analyses and informative censoring caused by patients
who were transplanted or lost to follow-up in other analyses
(i.e., responsiveness, MCID based on effect size and anchor-
based methods) is a potential concern, the percentage of patients
who were transplanted or lost to follow-up was low. For example,
from the trial baseline visit to the Week 48 visit (the follow-up
period used in some of the previously noted analyses), only 31
(2.7%) and 32 (2.7%) patients, respectively, were transplanted or
lost to follow-up, and this subgroup of patients was largely com-
parable with the rest of the population in terms of baseline char-
acteristics. As a result, the potential for any such bias is small.
The findings, combined with those of a previous study evalu-
ating the performance characteristics of the 6-minute-walk test in
TABLE 7. ESTIMATION OF THE MINIMAL CLINICALLY IMPORTANT DIFFERENCE IN
PERCENT-PREDICTED FVC IN PATIENTS WITH IPF
Standard Error of Measurement
N Mean SD Correlation SEM (95% CI)
% Predicted FVC 1,156 70.1 12.8 0.93 3.4 (3.2–3.5)
Effect Size
N Baseline Follow-up* Difference Effect Size
Mean % predicted FVC (SD) 984 70.8 (12.7) 67.4 (15.2) 23.4 (8.2) 0.27
Patient Referencing
N
Change in Percent-predicted FVC*
Unadjusted Mean (SD) Adjusted Mean (SD)†
Global change in health status‡
Much better 25 2.3 (7.3) 5.1 (7.3)
Somewhat better 55 22.1 (6.4) 0.7 (6.4)
Same 96 22.8 (5.8) 0 (5.8)
Somewhat worse 59 26.5 (6.6) 23.7 (6.6)
Much worse 14 26.1 (9.5) 23.3 (9.5)
Somewhat better or worse 114 2.3 (7.7) 2.2 (6.6)
Criterion Referencingx
N Percent-predicted FVC║ P Value¶
Hospitalization 0.226
No 929 70 (12.9)
Yes 213 71.1 (12.2)
Difference 1.2
Death ,0.001
No 1,037 70.7 (12.8)
Yes 105 64.9 (11.2)
Difference 5.8
Hospitalization or death 0.265
No 849 70.5 (12.9)
Yes 293 69.5 (12.4)
Difference 1
Definition of abbreviation: CI ¼ confidence interval.
* Assessed at the Week 48 study visit.
y Percent-predicted FVC values adjusted by mean value for group reporting no change in health status.
z Based on the SF-36 question: “Compared to one year ago, how would you rate your health in general now?”
Somewhat better and somewhat worse are considered to represent minimal but clinically important changes.
x Comparison of baseline percent-predicted FVC between patients who did and did not experience selected health
events during the subsequent 48-week period.
║ Data are presented as mean (SD).
¶ Independent samples t test.
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patients with IPF (32), provide two validated measures of clinical
status that can be used to assess the clinical efficacy of experi-
mental therapies in future trials in patients with IPF. Moreover,
the observation that 24-week change in FVC and 6MWD is pre-
dictive of 1-year mortality despite relatively weak correlations
between these and other measures of disease status suggests that
both tests measure clinically important domains of the disease
process that are not captured by other measures. Finally, the
establishment of a MCID for both percent-predicted FVC and
6MWD provides important benchmarks for assessing the clinical
significance of longitudinal changes in these parameters in
patients with IPF.
Importantly, the findings of this study do not militate against
current clinical practice, in which changes in both FVC andDLCO
are used to assess disease status. We believe, however, that our
findings provide robust reassurance about the performance
characteristics of the FVC measurement and provide the clini-
cian with an anchor around which to decide if any given change
is clinically meaningful. In this regard, we believe that the
MCID will be one of several factors that the clinician may use
in the assessment of disease progression and will be of value to
clinicians and researchers.
In conclusion, our results demonstrate that percent-predicted
FVC is a reliable, valid, and responsive measure of clinical status
in patients with IPF, and that a decline in percent-predicted FVC
of 2 to 6% represents a small but clinically important difference.
Collectively, these findings demonstrate that FVC is a clinically
useful measure of disease status and a valid endpoint for clinical
trials in patients with IPF.
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